MedTrace Logo

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

NCT00458978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2015-05-05

No results posted yet for this study

Summary

This phase II trial is studying how well cediranib maleate works in treating patients with recurrent or newly diagnosed metastatic head and neck cancer. Cediranib maleate may stop the growth of head and neck cancer by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Conditions

  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Verrucous Carcinoma
  • Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
  • Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
  • Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Recurrent Oral Cavity Verrucous Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Recurrent Salivary Gland Carcinoma
  • Salivary Gland Squamous Cell Carcinoma
  • Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
  • Stage IV Hypopharyngeal Squamous Cell Carcinoma
  • Stage IV Laryngeal Squamous Cell Carcinoma
  • Stage IV Laryngeal Verrucous Carcinoma
  • Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage IV Major Salivary Gland Carcinoma
  • Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
  • Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma
  • Stage IV Oral Cavity Verrucous Carcinoma
  • Stage IV Oropharyngeal Squamous Cell Carcinoma
  • Tongue Carcinoma
  • Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary

Interventions

DRUG

Cediranib Maleate

Given orally

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • James Rocco · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2013-05-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00458978 on ClinicalTrials.gov